Genetic Polymorphisms of IL-17F and TRAF3IP2 Could Be Predictive Factors of the Long-Term Effect of Infliximab against Crohn’s Disease

Table 6

Evaluation of a genetic test for response to IFX after 1 year of treatment of the CD patients with both concomitant use of immunomodulators and penetrating disease.

Factor	Number of CD patients (%)		OR (95% CI)	value
	Responders	Nonresponders
	= 4	= 5
Both G/G genotype of rs766748 in IL17F and C/C and C/A genotype of rs1883136 in TRAF3IP2	4 (100)	0 (0)	99.00 (1.618–6059)	0.0079
Others	0 (0)	5 (100)

Factors were statistically analyzed by Fisher’s exact test.
IFX: infliximab; CD: Crohn’s disease; OR: odds ratio; CI: confidence interval.